Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis

Authors: Jing Zhang, Huawei Jiang, Jiaofang Shao, Ruifang Mao, Jie Liu, Yingying Ma, Xuefeng Fang, Na Zhao, Shu Zheng, Biaoyang Lin

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

SOX4 is a transcription factor required for tissue development and differentiation in vertebrates. Overexpression of SOX4 has been reported in many cancers including glioblastoma multiforme (GBM), however, the underlying mechanism of actions has not been studied. In this study, we investigated the role of SOX4 in GBM.

Methods

Kaplan-Meier analysis was performed to assess the association between SOX4 expression levels and survival times in primary GBM samples. Cre/lox P system was used to generate gain or loss of SOX4 in GBM cells, and microarray analysis uncovered the regulation network of SOX4 in GBM cells.

Results

High SOX4 expression was significantly associated with good prognosis of primary GBMs. SOX4 inhibited the growth of GBM cell line LN229, A172G and U87MG, partly via the activation of p53-p21 signaling and down-regulation of phosphorylated AKT1. Gene expression profiling and subsequent gene ontology analysis showed that SOX4 influenced several key pathways including the Wnt/ beta-catenin and TGF-beta signaling pathways.

Conclusions

Our study found that SOX4 acts as a tumor suppressor in GBM cells by induce cell cycle arrest and inhibiting cell growth.
Appendix
Available only for authorised users
Literature
1.
Bowles J, Schepers G, Koopman P: Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000, 227 (2): 239-255. 10.1006/dbio.2000.9883.CrossRefPubMed
2.
Schepers GE, Teasdale RD, Koopman P: Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell. 2002, 3 (2): 167-170. 10.1016/S1534-5807(02)00223-X.CrossRefPubMed
3.
Pramoonjago P, Baras AS, Moskaluk CA: Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene. 2006, 25 (41): 5626-5639. 10.1038/sj.onc.1209566.CrossRefPubMed
4.
Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjot L, Orntoft T: SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 2006, 66 (7): 3434-3442. 10.1158/0008-5472.CAN-05-3456.CrossRefPubMed
5.
Lee S, Chen J, Zhou G, Shi RZ, Bouffard GG, Kocherginsky M, Ge X, Sun M, Jayathilaka N, Kim YC, Emmanuel N, Bohlander SK, Minden M, Kline J, Ozer O, Larson RA, LeBeau MM, Green ED, Trent J, Karrison T, Liu PP, Wang SM, Rowley JD: Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006, 103 (4): 1030-1035. 10.1073/pnas.0509878103.CrossRefPubMedPubMedCentral
6.
Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS: Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 2006, 66 (8): 4011-4019. 10.1158/0008-5472.CAN-05-3055.CrossRefPubMed
7.
Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009, 69 (23): 9038-9046. 10.1158/0008-5472.CAN-09-1499.CrossRefPubMedPubMedCentral
8.
Lin B, Madan A, Yoon JG, Fang X, Yan X, Kim TK, Hwang D, Hood L, Foltz G: Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One. 2010, 5 (4): e10210-10.1371/journal.pone.0010210.CrossRefPubMedPubMedCentral
9.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A. 2004, 101 (25): 9309-9314. 10.1073/pnas.0401994101.CrossRefPubMedPubMedCentral
10.
Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL, Horng JT, Hsiao M, Tsou AP: Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene. 2008, 27: 5578-5589. 10.1038/onc.2008.168.CrossRefPubMed
11.
Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu J, Chen L, Zhang K, Han L, Yu S, Pu P, Jiang T, Kang C: Nuclear translocation of beta-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol. 2012, 7 (4): 892-903. 10.1007/s11481-012-9354-3.CrossRefPubMed
12.
Judith M, De Bont JMK, Monique MCJ, Passier Roel E, Reddingius Peter AE, Sillevis S, Theo M, Luider Monique L, Den B, Rob P: Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro-Oncology. 2008, 10: 648-660. 10.1215/15228517-2008-032.CrossRef
13.
Andersen CL, Christensen LL, Thorsen K, Schepeler T, Sorensen FB, Verspaget HW, Simon R, Kruhoffer M, Aaltonen LA, Laurberg S, Ørntoft TF: Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer. 2009, 100 (3): 511-523. 10.1038/sj.bjc.6604884.CrossRefPubMedPubMedCentral
14.
Ahn SG, Kim HS, Jeong SW, Kim BE, Rhim H, Shim JY, Kim JW, Lee JH, Kim IK: Sox-4 is a positive regulator of Hep3B and HepG2 cells' apoptosis induced by prostaglandin (PG)A(2) and delta(12)-PGJ(2). Exp Mol Med. 2002, 34 (3): 243-249. 10.1038/emm.2002.34.CrossRefPubMed
15.
Kim BE, Lee JH, Kim HS, Kwon OJ, Jeong SW, Kim IK: Involvement of Sox-4 in the cytochrome c-dependent AIF-independent apoptotic pathway in HeLa cells induced by Delta12-prostaglandin J2. Exp Mol Med. 2004, 36 (5): 444-453. 10.1038/emm.2004.56.CrossRefPubMed
16.
17.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95 (2): 190-198. 10.3171/jns.2001.95.2.0190.CrossRefPubMed
18.
Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K: Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009, 5 (5): 504-514. 10.1016/j.stem.2009.08.018.CrossRefPubMed
19.
Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K, Miyazono K: Glioma-initiating cells retain their tumorigenicity through integration of the sox axis and Oct4. J Biol Chem. 2011, 286 (48): 41434-41. 10.1074/jbc.M111.300863.CrossRefPubMedPubMedCentral
20.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2 (5): 401-404. 10.1158/2159-8290.CD-12-0095.CrossRefPubMed
21.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013, 6 (269): l1-10.1126/scisignal.2004088.CrossRef
22.
23.
Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS: Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 2009, 69 (2): 709-717. 10.1158/0008-5472.CAN-08-3415.CrossRefPubMedPubMedCentral
24.
Bunting M, Bernstein KE, Greer JM, Capecchi MR, Thomas KR: Targeting genes for self-excision in the germ line. Genes Dev. 1999, 13 (12): 1524-1528. 10.1101/gad.13.12.1524.CrossRefPubMedPubMedCentral
25.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
26.
da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4 (1): 44-57. 10.1038/nprot.2008.211.CrossRefPubMed
27.
Huang DAW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA: DAVID Bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007, 35 (Web Server issue): W169-W175. 10.1093/nar/gkm415.CrossRefPubMedPubMedCentral
28.
Hur EH, Hur W, Choi JY, Kim IK, Kim HY, Yoon SK, Rhim H: Functional identification of the pro-apoptotic effector domain in human Sox4. Biochem Biophys Res Commun. 2004, 325 (1): 59-67. 10.1016/j.bbrc.2004.09.215.CrossRefPubMed
29.
Lee AK, Ahn SG, Yoon JH, Kim SA: Sox4 stimulates ss-catenin activity through induction of CK2. Oncol Rep. 2011, 25 (2): 559-565. 10.3892/or.2010.1104.CrossRefPubMed
30.
Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM: Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007, 27 (22): 7802-7815. 10.1128/MCB.02179-06.CrossRefPubMedPubMedCentral
31.
Saegusa M, Hashimura M, Kuwata T: Sox4 functions as a positive regulator of beta-catenin signaling through upregulation of TCF4 during morular differentiation of endometrial carcinomas. Lab Investig J Tech Meth Pathol. 2012, 92 (4): 511-521. 10.1038/labinvest.2011.196.CrossRef
32.
Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, Yang JM, Oh ST, Kim DG, Wang HJ, Lee SB, Yoon SK: SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis. 2010, 31 (7): 1298-1307. 10.1093/carcin/bgq072.CrossRefPubMed
33.
Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B: Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS. 2009, 13 (4): 345-354. 10.1089/omi.2009.0008.CrossRefPubMed
34.
Pan X, Zhao J, Zhang WN, Li HY, Mu R, Zhou T, Zhang HY, Gong WL, Yu M, Man JH, Zhang PJ, Li AL, Zhang XM: Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci U S A. 2009, 106 (10): 3788-3793. 10.1073/pnas.0810147106.CrossRefPubMedPubMedCentral
35.
Tang HY, Zhao K, Pizzolato JF, Fonarev M, Langer JC, Manfredi JJ: Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. J Biol Chem. 1998, 273 (44): 29156-29163. 10.1074/jbc.273.44.29156.CrossRefPubMed
36.
Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y: Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem. 2002, 277 (24): 21843-21850. 10.1074/jbc.M109745200.CrossRefPubMed
37.
Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000, 182 (3): 311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.CrossRefPubMed
38.
Sarkar A, Hochedlinger K: The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013, 12 (1): 15-30. 10.1016/j.stem.2012.12.007.CrossRefPubMedPubMedCentral
39.
England B, Huang T, Karsy M: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 2013, 34 (4): 2063-2074. 10.1007/s13277-013-0871-3.CrossRefPubMed
40.
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 1994, 54 (3): 649-652.PubMed
41.
Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer. 2002, 2 (8): 594-604. 10.1038/nrc864.CrossRefPubMed
42.
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995, 82 (4): 675-684. 10.1016/0092-8674(95)90039-X.CrossRefPubMed
43.
44.
Jang SM, Kang EJ, Kim JW, Kim CH, An JH, Choi KH: Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA. Biochem Biophys Res Commun. 2013, 438 (2): 445-451. 10.1016/j.bbrc.2013.07.099.CrossRefPubMed
45.
Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M, Klein-Hitpass L, Moroy T, Mossner J, Engeland K: Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene. 2004, 23 (19): 3376-3384. 10.1038/sj.onc.1207464.CrossRefPubMed
Metadata
Title
SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis
Authors
Jing Zhang
Huawei Jiang
Jiaofang Shao
Ruifang Mao
Jie Liu
Yingying Ma
Xuefeng Fang
Na Zhao
Shu Zheng
Biaoyang Lin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-014-0207-y

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Case report

Symptomatic aggravation after corticosteroid pulse therapy in definite sporadic Creutzfeldt-Jakob disease with the feature of Hashimoto's encephalopathy

Research article

Association between neuromyelitis optica and tuberculosis in a Chinese population

Study protocol

Prediction of outcome in patients with suspected acute ischaemic stroke with CT perfusion and CT angiography: the Dutch acute stroke trial (DUST) study protocol

Research article

Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis

Study protocol

Long term cerebral and vascular complications after irradiation of the neck in head and neck cancer patients: a prospective cohort study: study rationale and protocol

Research article

Application of principles of exercise training in sub-acute and chronic stroke survivors: a systematic review